Cost of Product Discontinuations in the Pharmaceutical Industry

Older drugs often provide more affordable treatment options due to higher market competition after the patent expires or because they are exposed to price regulations. This research team will investigate pharmaceutical firms’ decisions to strategically discontinue old drugs when introducing new or improved versions. The study will examine the impact of voluntary drug discontinuations, which are unrelated to safety concerns, on adherence to treatment, cost of treatment, and consumer surplus.